We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

145 hedge funds and large institutions have $362M invested in Cullinan Therapeutics in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 37

1% more funds holding

Funds holding: 143 → 145 (+2)

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

2.7% less ownership

Funds ownership: 106.09% → 103.39% (-2.7%)

25% less capital inflows, than outflows

Capital inflows: $35.8M | Capital outflows: $47.5M

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

38% less call options, than puts

Call options by funds: $175K | Put options by funds: $280K

Holders
145
Holders Change
+2
Holders Change %
+1.4%
% of All Funds
1.89%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
28
Increased
56
Reduced
37
Closed
26
Calls
$175K
Puts
$280K
Net Calls
-$105K
Net Calls Change
+$7.34M

CGEM Hedge Fund Activity: Q3 2025 in Review

145 of the 7,664 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q3 2025, worth a combined $362M — down 23% from $471M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CGEM positions and 26 closed out — a net gain of 2 holders — while 56 added to existing stakes and 37 trimmed.

The largest buyer was Lynx1 Capital Management, adding an estimated $10M. The largest seller was Deerfield Management, cutting an estimated $6.8M.

  • 145 institutional investors held Cullinan Therapeutics (CGEM) as of Q3 2025, up from 143 in Q2 2025.
  • Funds reported $362M of Cullinan Therapeutics stock for Q3 2025, down 23% quarter-over-quarter.
  • 28 funds opened new Cullinan Therapeutics positions in Q3 2025 and 26 closed out, a net change of +2 holders.
  • The largest Cullinan Therapeutics buyer in Q3 2025 was Lynx1 Capital Management, an estimated $10M added.
  • The largest Cullinan Therapeutics seller in Q3 2025 was Deerfield Management, an estimated $6.8M sold.

Based on aggregated 13F filings for Q3 2025.